ActA mediates cross-talk between breast cancer cells and cancer-associated fibroblasts in the lung metastatic niche that enhances fibrosis and metastasis, implicating ActA as a potential therapeutic ...

Mesothelin secretion by cancer cells supports pancreatic cancer metastasis by inducing macrophage secretion of VEGFA and S100A9 to support cancer cell proliferation and survival, recruit neutrophils, ...

1Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational ...

3Department of Biology, Stanford University, Stanford, California. 5Cancer Biology Program, Stanford University School of Medicine, Stanford, California. 12Chan Zuckerberg Biohub, San Francisco, ...

In MTAP-deficient cancer cells, PRMT5 expression and activity is preferentially required for cell growth. Major finding: In MTAP-deficient cancer cells, PRMT5 expression and activity is preferentially ...

1Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California. 2Cancer Institute, Stanford University School of Medicine, Stanford, ...

Abstract. Binding of steroid hormones to their cognate receptors regulates the growth of most prostate and breast cancers. We hypothesized that CYP11A inhibition might halt the synthesis of all ...

1Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. *Corresponding Author: Cari M. Kitahara, Division of ...

1Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, France.

The discovery and characterization of novel WRN helicase inhibitors provides pharmacological validation for the clinical development of WRN inhibitors for the treatment of patients with MSI tumors.

1Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, New York.

Cancer Res (2023) 83 (7_Supplement): 526. RMC-9805 treatment caused selective and persistent modification of KRAS G12D leading to deep and durable suppression of RAS pathway activity, inhibition of ...